IDL

(redirected from intermediate-density lipoprotein)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

IDL

(language)
This article is provided by FOLDOC - Free Online Dictionary of Computing (foldoc.org)

IDL

(1) (Interface Definition Language, Interface Description Language) A language used to describe the interface to a software component or routine in a manner that is not dependent on a particular programming language or operating system. Because an IDL is independent of language and machine, it enables communications between applications running in different operating environments. For example, the Web Services Description Language (WSDL) discloses the interface for routines that provide Web services. Likewise, the CORBA system, a service oriented architecture (SOA) that predates Web services, uses an IDL. See WSDL and CORBA.

(2) (Interactive Data Language) An interpreted programming language from ITT Visual Information Solutions, Boulder, CO (www.ittvis.com), formerly Research Systems, Inc., that runs on Windows, Mac and various Unix platforms. It is used to write image processing and visualization applications. Well known products written in IDL include Research Systems' own ENVI software and the RiverTools application from Rivix, LLC.

A Scientific and Aerospace Influence
Initially created for NASA astronomers by David Stern, founder of RSI in 1977, IDL provides high-level commands for accessing images, performing data analyses and displaying 3D objects. IDL includes a complete development environment and also comes as an ActiveX control so that its routines can be accessed from user interfaces written in other languages such as Visual Basic. IDL On the Net, or ION, is a family of products that lets applications be shared across a network. IDL VM (Virtual Machine) is a free runtime utility that allows distribution of compiled IDL code applets.

In 2000, Eastman Kodak acquired RSI as a wholly owned subsidiary, then sold it to ITT Corporation in 2004, along with its Remote Sensing Systems division.
Copyright © 1981-2019 by The Computer Language Company Inc. All Rights reserved. THIS DEFINITION IS FOR PERSONAL USE ONLY. All other reproduction is strictly prohibited without permission from the publisher.
References in periodicals archive ?
IDL: Intermediate-density lipoprotein; an inherited, independent risk factor for heart disease.
Beyond fasting triglycerides and VLDL, there is a measure of postprandial lipoproteins that is reliable and readily available: intermediate-density lipoprotein (IDL).
The number combines the levels of highly atherogenic very-low-density lipoprotein and intermediate-density lipoprotein, as well as LDL.
(3) reported that RemL-C correlated with remnant-like lipoprotein particle cholesterol (RLP-C) in the general population, but the RemL-C assay was likely to reflect intermediate-density lipoprotein more closely than RLP-C.
[4] Nonstandard abbreviations: CVD, cardiovascular disease; ATP, Adult Treatment Panel III; apo, apolipoprotein; IDL, intermediate-density lipoprotein; IM, ion mobility; VLDL, very-low-density lipoprotein; DMA, differential mobility analyzer; RGD, reactive green 19 dextran; LOD, limit of detection; LOQ, limit of quantification.
Non-high-density lipoprotein (HDL) cholesterol is defined as the difference between total and HDL cholesterol and includes potential proatherogenic apolipoprotein B-containing particles such as low-density lipoprotein (LDL), intermediate-density lipoprotein and very-low-density lipoprotein as well as chylomicron remnants and lipoprotein (a) (1).
ApoB-100 is synthesized in the liver and is an essential structural and functional component of VLDL and its metabolic products, intermediate-density lipoprotein (IDL) and LDL, being the ligand for the LDL receptor.
Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease.
To test this idea, we determined the lipoprotein particle distribution of PCSK9 by immunoprecipitating highly purified VLDL, HDL, LDL, intermediate-density lipoprotein, and chylomicron particle fractions or unfractionated serum with anti-PCSK9-3 antibody.
In conjunction with these previous studies, the increase of small VLDL-C in CAD patients also supports the concept that smaller, partially catabolized triglyceride-rich lipoprotein (VLDL remnants) and/or a part of intermediate-density lipoprotein are atherogenic.
The reason for this discrepancy was unclear and may have been related to differential estimation of some abnormal lipoproteins such as intermediate-density lipoprotein remnants, or small, dense LDL.

Full browser ?